Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura [2] J Clin Pharmacol. 2022 Mar;62(3):409-421. Bergstrand M, Hansson E, Delaey B, Callewaert F, Sousa RP, Sargentini-Maier ML. HematologyJournalMIDDPharmacometricsSpecial/specific populations Pharmetheus Affiliates Senior Consultant, Regulatory Affairs Emma Hansson See bio Principal Consultant & MIDD Platform Scientific Lead Martin Bergstrand See bio Quality Control and Medical Writer Viviana Moroso See bio